Company: PBH
Filing Date: 2025-02-06
Form Type: 10-Q
Source: 0001295947-25-000009
Chunk: 12

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-02-06
Form: 10-Q
Item: Item 2
Chunk 12
---
intestinal26,469 9.2 22,707 8.0 3,762 16.6 Eye & Ear Care6,783 2.3 6,569 2.3 214 3.3 Dermatologicals2,109 0.7 1,165 0.4 944 81.0 Oral Care3,211 1.1 3,100 1.1 111 3.6 Other OTC357 0.1 45 — 312 693.3 Total International OTC Healthcare51,383 17.7 46,176 16.3 5,207 11.3 Total Consolidated$290,317 100.0 $282,741 100.0 $7,576 2.7 

Total revenues for the three months ended December 31, 2024 were $290.3 million, an increase of $7.6 million, or 2.7%, versus the three months ended December 31, 2023.

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment increased $2.4 million, or 1.0%, during the three months ended December 31, 2024 versus the three months ended December 31, 2023.  The $2.4 million increase was primarily attributable to an increase in sales in the Gastrointestinal and Dermatologicals categories, partly offset by a decrease in sales in the Cough & Cold category.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $5.2 million, or 11.3%, during the three months ended December 31, 2024 versus the three months ended December 31, 2023. The $5.2 million increase was primarily attributable to an increase in sales in the Gastrointestinal category.

-24-

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.

Three Months Ended December 31, (In thousands)Increase (Decrease)Gross Profit2024%2023%Amount%North American OTC Healthcare$130,867 54.8 $130,475 55.2 $392 0.3 International OTC Healthcare30,182 58.7 27,463 59